{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Ventyx Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"VTYX"},"Address":{"label":"Address","value":"662 ENCINITAS BOULEVARD,SUITE 250, ENCINITAS, California, 92024, United States"},"Phone":{"label":"Phone","value":"+1 760 593-4832"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors."},"CompanyUrl":{"label":"Company Url","value":"https://www.ventyxbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"John M. Nuss","title":"Chief Scientific Officer"},{"name":"Matthew Moore","title":"Chief Operating Officer"},{"name":"Raju S. Mohan","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}